Autophagy: a novel target in order to overcome drug resistance in pancreatic adenocarcinoma
Open Access
- 29 October 2025
- journal article
- review article
- Published by The Royal Society in Open Biology
- Vol. 15 (10) , 240412
Abstract
Typically, unchecked pancreatic cell proliferation results in the development of pancreatic cancer, which has the potential to spread to other bodily organs. About 90% of instances of pancreatic cancer are pancreatic adenocarcinomas. About 10–20% of pancreatic carcinomas are resectable and potentially curable, and the 5-year survival rate is only 4%; as a result, the majority of pancreatic cancer treatments are palliative in nature. Surgical resection is the only curative treatment; however, because of late diagnosis, the majority of patients appear at an advanced stage, and only a small percentage (10–20%) of them are candidates for surgery. Due to pancreatic cancer’s strong resistance to practically all chemotherapeutic drugs and conventional radiotherapies, conventional radiation and chemotherapies have little effectiveness in extending patients’ overall life. A lot of scientific studies, however, frequently use the metaphorical term ‘double-edged sword’ to indicate how autophagy plays a different function in cancer. The use of autophagy inhibitors is thought to be advantageous in combining antineoplastic drugs to improve the sensitivity of cancer cells to therapeutic compounds that activate autophagy. In this review, we aim to look into autophagy along with searching for the most effective strategy in order to treat pancreatic adenocarcinoma with the least drug resistance.Keywords
This publication has 121 references indexed in Scilit:
- Bcl-2 Antiapoptotic Proteins Inhibit Beclin 1-Dependent AutophagyCell, 2005
- Apoptotic and autophagic cell death induced by histone deacetylase inhibitorsProceedings of the National Academy of Sciences, 2004
- A Phase I Trial of the Dual Farnesyltransferase and Geranylgeranyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Pancreatic CancerClinical Cancer Research, 2004
- Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouseCancer Cell, 2003
- A “catastrophic hypothesis” for pancreas cancer progression1 1The author thanks J. Alguacil, D. Longnecker, N. Malats, X. Mayol, M. Porta, and A. Sodhi for valuable comments and suggestions to a prior version of this manuscript, as well as for many stimulating discussions and J. Franquesa for the artwork.Gastroenterology, 2003
- The pre‐autophagosomal structure organized by concerted functions of APG genes is essential for autophagosome formationThe EMBO Journal, 2001
- Cellular autophagic capacity is highly increased in azaserine-induced premalignant atypical acinar nodule cellsCarcinogenesis, 1999
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Pancreatic adenocarcinoma: epidemiology and genetics.Journal of Medical Genetics, 1996
- Isolation of autophagic vacuoles from rat liver: morphological and biochemical characterization.Journal of Cell Biology, 1982